Items tagged with Treatment
An oral antidiabetic drug shows promise for treating tuberculosis (post)
The drug metformin, already used in the USA to treat type 2 diabetes, also enhances the body's immune response to tuberculosis, according to A*STAR researchers.
STREAM clinical trial reaches recruitment target (post)
24 June 2015 - The STREAM clinical trial has enrolled its 400th patient, meeting the recruitment target for Stage 1 of the comparison of a shorter 9-month treatment regimen for multidrug-resistant tuberculosis (MDR-TB) with the World Health Organization-approved treatment regimen.
DR-TB Scale-up Treatment Action Team (STAT) (post)
25 June 2015 - In March 2015, Médecins Sans Frontières (MSF), ACTION Global Health Advocacy Partnership, SWIFT Response Project, Treatment Action Campaign (TAC), Treatment Action Group (TAG) and 84 other organisations issued a call to action urging global health actors and the TB community to form a consortium with the objective of meeting time-bound, concrete targets for scaling up use of new drugs in DR-TB treatment.
Psychological distress and its relationship with non-adherence to TB treatment: a multicentre study (post)
Abstract
Risk factors for acquisition of drug resistance during multidrug-resistant tuberculosis treatment, Arkhangelsk Oblast, Russia, 2005–2010 (post)
Abstract
India: Nudge to tweak TB treatment rules (post)
New Delhi, July 6: India could prevent on average 18,000 people from developing multi-drug-resistant tuberculosis every year over the next decade if the health ministry accelerates proposed changes in TB diagnosis and treatment policies, public health experts have said.
Linezolid for XDR-TB — final study outcomes (post)
We previously reported 4-month culture conversion rates among patients with chronic extensively drug-resistant tuberculosis (XDR-TB) who received linezolid (1). By 4 months, 15 of 19 patients (79%) in the immediate-start group and 7 of 20 (35%) in the delayed-start group had conversion to a negative sputum culture (P=0.001). After 6 months of linezolid treatment, 34 of 39 patients (87%) had negative sputum cultures. Here, we report final study outcomes for these patients 1 year after the end of treatment, 36 months after they began the study.
Delamanid for extensively drug-resistant tuberculosis (post)
New therapies are needed to address the imminent rise of drug-resistant infections. Delamanid is one of two new drugs approved for the treatment of multidrug-resistant tuberculosis (MDR-TB) in the past 40 years. The clinical evaluation of delamanid included a subgroup of patients with extensively drug-resistant tuberculosis (XDR-TB), which is more difficult to treat than MDR-TB. This evaluation provides an opportunity for a post hoc analysis of outcomes.
Towards host-directed therapies for tuberculosis (post)
The treatment of tuberculosis is based on combinations of drugs that directly target Mycobacterium tuberculosis. A new global initiative is now focusing on a complementary approach of developing adjunct host-directed therapies.
MSU scientists set sights on glaucoma medication to treat TB (post)
EAST LANSING, Mich. - A new discovery by Michigan State University scientists suggests that a common medication used to treat glaucoma could also be used to treat tuberculosis, even the drug-resistant kind.
Page 13 of 108 · Total posts: 0
←First 12 13 14 Last→